GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Total Receivables

Lumos Diagnostics Holdings (ASX:LDX) Total Receivables : A$2.38 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Total Receivables?

Lumos Diagnostics Holdings's Total Receivables for the quarter that ended in Dec. 2023 was A$2.38 Mil.


Lumos Diagnostics Holdings Total Receivables Historical Data

The historical data trend for Lumos Diagnostics Holdings's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Total Receivables Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23
Total Receivables
2.69 2.22

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Total Receivables Get a 7-Day Free Trial 2.82 2.69 2.34 2.22 2.38

Lumos Diagnostics Holdings Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Lumos Diagnostics Holdings Total Receivables Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Diagnostics Holdings (ASX:LDX) Business Description

Traded in Other Exchanges
Address
2724 Loker Ave West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines